CLINICAL VALUE OF BONE REMODELING MARKERSIN BREAST CANCER PATIENTSWITH SKELETAL METASTASES

N.V. Lyubimova (1), G.V. Kozarskaya (2), T.V. Ageeva (1), S.M. Portnoy (1), A.V. Maslyaev (1), N.E.Kushlinsky (1)
1 -Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Re-search Center of the Russian Academy of Medical Sciences,
2 -State Budgetary Establishment of Healthcare «Oncological dispensary №5 of the Moscow Healthcare Department»

The dependence of biochemical markers of bone resorption (C-terminal telopeptide of type I collagen – b-CTx, deoxypyridinoline – DPID, tartrate-resistant acid phosphatase (TRAP) 5b) and osteosynthesis (bone alkaline phosphatase – BALP) on clinical manifestations of bone metastases in 239 patients with breast cancer (BC) has been established with the use of ELISA method. In patients with bone metastases (n=72) DPID excretion in the urine, and the seru concentration of CTx and activity of TRAP and BALP level were found to be significantly higher if compared with BC patients without bone lesions (n=167), and healthy females (n=47). However, their significant increase (p
Keywords: 
deoxypyridinoline, C-terminal telopeptide of type I collagen, tartrate resistant acid phosphatase 5b, bone alkaline phosphatase, prognosis, bone metastases, breast cancer